Behçet’s Syndrome

Abstract

To the Editor: In their review, Saadoun et al. (Feb. 15 issue)1 discuss recent developments related to Behçet’s syndrome. Inflammation-driven endothelial-cell dysfunction is the main cause of thromboembolism in patients with Behçet’s syndrome.2 Glucocorticoids and immunosuppressants are standard care in these cases. However, the authors’ statement that the role of anticoagulants is uncertain might be misleading, and the decision about using them remains dependent on the clinical context and pathophysiological features. For example, it was found that antiphospholipid antibodies may be present in patients with Behçet’s syndrome during thrombotic events, with an estimated prevalence as high as 50% in some .